Video encyclopedia



The Role of Glutamatergic Signaling in Major Depressive Disorder


TSC-related epilepsy medicine pipeline

Basimglurant (INN) is a negative allosteric modulator of the mGlu5 receptor which is under development by Roche and Chugai Pharmaceutical for the treatment of treatment-resistant depression and fragile X syndrome. As of November 2016, it has undergone phase II clinical trials for both of these indications.
Explore contextually related video stories in a new eye-catching way. Try Combster now!
  • Pharmacology 

  • Clinical trials